Description:
3SBio Inc. is an integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China. The Company’s recombinant, or genetically engineered, protein-based products and product candidates are designed to address markets with unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases. Its principal products are EPIAO and TPIAO, and its legacy products are Intefen and Inleusin. EPIAO is an injectable recombinant human erythropoietin (EPO) that is used to stimulate the production of red blood cells in patients with anemia and to reduce the need for blood transfusions. 3SBio Inc. had launched TPIAO, its internally developed protein-based therapeutic product. In addition to EPIAO and TPIAO, the Company markets two other protein-based therapeutics.

Officers and Directors:
Dan Lou Chairman of the Board
Age: 74

Jing Lou Chief Executive Officer, Director
Age: 46

Bo Tan Chief Financial Officer
Age: 36

David Chen Chief Operating Officer, Executive Vice President
Age: 44

Bin Huang Vice President - Human Resources, Director
Age: 48

Liping Xu Vice President, Director
Age: 55

Yingfei Wei Chief Scientific Officer, Vice President - Business Development
Age: 48

Dongmei Su Chief Technology Officer
Age: 39

Norman Tong Controller
Age: 40

Ke Li Corporate Secretary
Age: 41

Contact:
No. 3 A1, Road 10 Shenyang Economy & Technology Development Zone
Shenyang, LIA 110027
China
+86-24-25811820 (Phone)